TVAX Biomedical, Inc.
TVAX Immunotherapy is a new approach to the treatment of cancer offering the promise of improved clinical outcomes and reduced side effects.
TVAX Biomedical is advancing a Phase 3-ready brain cancer program. The company's unique therapy combines personalized cancer cell vaccination and “killer” T cell treatment without the undesirable side effects associated with radiation and chemotherapy. The TVAX advantage within the cancer immunotherapy space is that TVAX is the first and currently only company in the world to combine these two approaches into one potent treatment platform.